Neomorph

The company says its proprietary target space for molecular glues includes numerous degrons and E3 ubiquitin ligases.

The page provides Neomorph news, press releases and updates on its pipeline.

Bell Zhong is Chief Financial Officer of Neomorph and has over 17 years of finance and investment banking experience. Bell Zhong has helped execute over $35bn in equity and equity linked transactions and more than $100bn in M&A transactions.

Dr. Wagner has over 20 years of cancer research and clinical drug development experience. At Boundless Bio, he guided clinical development of therapeutics for patients with oncogene amplifications; at Inhibrx, he built and led a clinical development organization.

Megan Gates is Neomorph’s Vice President of Talent Acquisition, leading recruitment strategy, workforce planning and talent brand development. She previously led global talent acquisition for research and early development at Bristol Myers Squibb.

Rohan Beckwith is Neomorph’s Sr. Vice President of Chemistry, with over 15 years in drug discovery and seven in targeted protein degradation. At the Novartis Institutes for BioMedical Research, he helped build a molecular glue degrader platform and deliver a clinical candidate.

Neomorph uses its discovery platform to identify molecular glues intentionally rather than by random chance.

Developing molecular glue degraders to accomplish what many have deemed impossible: the ability to target and destroy every disease-causing protein.

Neomorph, Inc.’s privacy policy explains its online information practices in connection with the company website.